MREO (Mereo BioPharma Group) Moat Score: 3/10 (As of Jul. 06, 2026)


MREO Mereo BioPharma Group PLC MREO
19 GF Score
Price $0.32
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group Moat Score?

Mereo BioPharma Group MREO -5.41% 19 Moat Score is 3 as of Jul. 06, 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,395 Biotechnology companies, Mereo BioPharma Group ranks better than 75.56% on this metric.

Mereo BioPharma Group has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Mereo BioPharma Group has No Moat: Mereo BioPharma Group PLC operates in the biotech sector with high competition and uncertain product success. It lacks significant intellectual property or regulatory barriers to establish a sustainable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Mereo BioPharma Group might have No Moat - Very weak/transient advantages.

Mereo BioPharma Group  (NAS:MREO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Mereo BioPharma Group Moat Score Related Terms

MREO vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Mereo BioPharma Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Moat Score falls into.


MREO
19GF Score
Mereo BioPharma Group PLC MREO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Mereo BioPharma Group (MREO) has a Moat Score of 3 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Mereo BioPharma Group ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Mereo BioPharma Group's Moat Score too high?
Mereo BioPharma Group's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Mereo BioPharma Group's value of 3 is 50% above this industry median. Based on the distribution chart, Mereo BioPharma Group ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mereo BioPharma Group ranks #341 out of 1395 companies for Moat Score. This places Mereo BioPharma Group in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Mereo BioPharma Group's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mereo BioPharma Group's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mereo BioPharma Group's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current Moat Score is 3 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mereo BioPharma Group Business Description

Other Exchanges 0A9G:UKMAH0:Germany
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score

Get the complete analysis for MREO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price